AnaptysBio (NASDAQ:ANAB) had its price target lifted by research analysts at Jefferies Group from $6.59 to $145.00 in a research note issued on Monday, The Fly reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Jefferies Group’s target price would suggest a potential upside of 14.67% from the stock’s previous close.
Other equities research analysts have also issued reports about the stock. Wedbush reiterated a “positive” rating and issued a $82.00 target price (up from $75.00) on shares of AnaptysBio in a report on Tuesday, November 7th. SunTrust Banks increased their price objective on shares of AnaptysBio from $115.00 to $162.00 and gave the stock a “buy” rating in a research report on Thursday. ValuEngine raised shares of AnaptysBio from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Zacks Investment Research downgraded shares of AnaptysBio from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. Finally, Robert W. Baird reissued a “buy” rating and set a $144.00 price objective (up previously from $81.00) on shares of AnaptysBio in a research report on Friday, January 19th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $112.00.
Shares of AnaptysBio (NASDAQ:ANAB) opened at $126.45 on Monday. The company has a quick ratio of 10.77, a current ratio of 10.77 and a debt-to-equity ratio of 0.09. AnaptysBio has a twelve month low of $18.15 and a twelve month high of $132.46.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.